Neoadjuvant chemotherapy with a combination of pegylated liposomal doxorubicin (Caelyx®) and paclitaxel in locally advanced breast cancer: a phase II study by the Hellenic Cooperative Oncology Group-Reference-Cited by-同舟云学术

Neoadjuvant chemotherapy with a combination of pegylated liposomal doxorubicin (Caelyx®) and paclitaxel in locally advanced breast cancer: a phase II study by the Hellenic Cooperative Oncology Group

Published:2002-11 Issue:11 Volume:13 Page:1737-1742
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Gogas H.,Papadimitriou C.,Kalofonos H.P.,Bafaloukos D.,Fountzilas G.,Tsavdaridis D.,Anagnostopoulos A.,Onyenadum A.,Papakostas P.,Economopoulos T.,Christodoulou C.,Kosmidis P.,Markopoulos C.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/13/11/1737/532338/mdf284.pdf

Reference18 articles.

1. Systemic treatment for locally advanced breast cancer. What we still need to learn after a decade of multimodality clinical trials;Piccart;Eur J Cancer,1992

2. Liposomal doxorubicin antitumor activity and unique toxicities during two complementary phase I studies;Uziely;J Clin Oncol,1995

3. Treatment of advanced breast cancer with sterically stabilized lipoosomal doxorubicin. Results of a multicenter phase II trial;Ranson;J Clin Oncol,1997

4. Taxanes in the treatment of breast cancer: a prodigy comes of age;Miller;Cancer Invest,1999

5. Paclitaxel: an angiogenesis antagonist in a metastatic breast cancer model;Lau;Proc Am Soc Clin Oncol,1998

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of the Efficacy, Safety, and Quality of Life of Pegylated Liposomal Doxorubicin-Cyclophosphamide versus Epirubicin-Cyclophosphamide in Patients with Early-Stage HER2-Negative Breast Cancer: A Prospective, Randomized, Multicenter, Phase II Study;Oncology Research and Treatment;2024-07-19

2. The Survival Benefit of Pegylated Liposomal Doxorubicin-Based Neoadjuvant Chemotherapy in the Management of Breast Cancer;Cancer Biotherapy and Radiopharmaceuticals;2024-03-21

3. The survival benefit of Pegylated Liposomal Doxorubicin-Based Neoadjuvant Chemotherapy in the management of breast cancer;2024-01-02

4. Non-pegylated liposomal doxorubicin in older adjuvant early breast cancer patients: cardiac safety analysis and final results of the COLTONE study;Clinical and Experimental Medicine;2023-08-27

5. Cancer nanomedicine in preoperative therapeutics: Nanotechnology-enabled neoadjuvant chemotherapy, radiotherapy, immunotherapy, and phototherapy;Bioactive Materials;2023-06